about
Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in miceRapid molecular detection of rifampicin resistance facilitates early diagnosis and treatment of multi-drug resistant tuberculosis: case control studyRapid genotypic detection of rifampin- and isoniazid-resistant Mycobacterium tuberculosis directly in clinical specimensCombating Tuberculosis Infection: A Forbidding ChallengeSynthesis and structural activity relationship study of antitubercular carboxamidesUnique mechanism of action of the thiourea drug isoxyl on Mycobacterium tuberculosisUse of germicides in the home and the healthcare setting: is there a relationship between germicide use and antibiotic resistance?Advocacy, promotion and e-learning: Supercourse for zoonosisAssociation between diabetes mellitus and multi-drug-resistant tuberculosis: a protocol for a systematic review and meta-analysisDifferential producibility analysis (DPA) of transcriptomic data with metabolic networks: deconstructing the metabolic response of M. tuberculosisSynthesis, antitubercular activity and mechanism of resistance of highly effective thiacetazone analoguesThe structure of MbtI from Mycobacterium tuberculosis, the first enzyme in the biosynthesis of the siderophore mycobactin, reveals it to be a salicylate synthaseCharacterization of Mycobacterium tuberculosis Rv3676 (CRPMt), a cyclic AMP receptor protein-like DNA binding protein.The challenge of emerging and re-emerging infectious diseasesAudiologic monitoring of multi-drug resistant tuberculosis patients on aminoglycoside treatment with long term follow-upNew anti-tuberculosis agents amongst known drugs.Mycobacterium tuberculosis Rv3586 (DacA) is a diadenylate cyclase that converts ATP or ADP into c-di-AMP.Primary antimicrobial resistance among Mycobacterium tuberculosis isolates from HIV seropositive and HIV seronegative patients in Dar es Salaam Tanzania.High-throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv.Antituberculosis activity of the molecular libraries screening center network library.Primary multidrug-resistant tuberculosis versus drug-sensitive tuberculosis in non-HIV-infected patients: Comparisons of CT findingsEvaluation of molecular tools for detection and drug susceptibility testing of Mycobacterium tuberculosis in stool specimens from patients with pulmonary tuberculosis.Susceptibility Pattern and Epidemiology of Mycobacterium tuberculosis in United Emirati HospitalAntimycobacterial agents differ with respect to their bacteriostatic versus bactericidal activities in relation to time of exposure, mycobacterial growth phase, and their use in combinationEvaluation of the anti-mycobacterium tuberculosis activity and in vivo acute toxicity of Annona sylvatic.Targeting tuberculosis through a small focused library of 1,2,3-triazoles.Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin.In vitro susceptibility of Mycobacterium tuberculosis clinical isolates to garenoxacin and DA-7867Unique transcriptome signature of Mycobacterium tuberculosis in pulmonary tuberculosis.Time to develop capacity to diagnose drug resistant tuberculosis.Extensively Drug-Resistant Tuberculosis: A Sign of the Times and an Impetus for Antimicrobial Discovery.Comparison of two commercially available DNA line probe assays for detection of multidrug-resistant Mycobacterium tuberculosis.Evaluation of MGIT 960-based antimicrobial testing and determination of critical concentrations of first- and second-line antimicrobial drugs with drug-resistant clinical strains of Mycobacterium tuberculosis.Drug targets in mycobacterial sulfur metabolism.New targets and inhibitors of mycobacterial sulfur metabolism.Tuberculosis control strategies to reach the 2035 global targets in China: the role of changing demographics and reactivation diseaseWhich agents should we use for the treatment of multidrug-resistant Mycobacterium tuberculosis?Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens.Tuberculosis due to resistant Haarlem strain, Tunisia
P2860
Q21034169-76DAF6EE-6FB6-4F28-B4BC-78B1C94DDB92Q21090145-19A2F317-FE03-41FB-9878-B4929DA93676Q21144235-30119BF6-5C2B-444C-8486-0007CE8F4961Q24549191-26C92624-0E5B-4199-AD63-363828099A36Q26750683-5946BB38-F582-44F6-9BCC-FD9E2490A2B5Q28084238-5436BCEE-1304-496D-A8DE-FB8566759541Q28210003-27AEC2B0-7C44-445D-B231-0759D85355B6Q28265803-E1F3A2CC-891D-44B2-A872-5AE8B0438691Q28390170-92C49C76-ACDA-4BF3-9F8B-78E7E0053ADDQ28468566-EBB7C78B-61FB-4A7A-9480-680F594DD40DQ28478889-919835B6-2A97-4FE7-9B24-0E2EF0814DA9Q28484824-ADDFACDE-BA91-40B7-8F01-544363561CA8Q28486666-AFE2CF47-8F67-4147-B00A-0AF9DAEBBFC3Q28487330-BB742BCD-B3DB-430F-80FF-A70AFA6D5263Q29617354-0AEF10D3-789B-4854-AC90-85BBDEFE582BQ30838132-B7B28480-0F30-4CDA-938C-D65C134B5A12Q30872520-0D567105-311E-480B-80E3-1EFA9CAC5C37Q31058151-74F03796-7E62-43A8-A112-8BB9C397EA62Q33360959-1879FED8-396B-4605-905E-20BD510B044FQ33503956-CEB4781B-A5E8-4BE6-8399-2879F86AF1C7Q33506893-18A5949F-87B1-4B30-AC85-7E5F657EC800Q33769023-5FE80547-D257-4975-82D0-A752E42C8458Q33827194-F6C4AFFB-43ED-4417-A09B-42EAEF5CBDD4Q33829247-BE4B3440-E83D-4A20-A584-6300B54B64E1Q33836497-8BE8724E-ACEA-4449-834D-43120B52C942Q33849036-53E58AA2-454A-41D1-9B2D-C95AB4E10F9EQ33919844-754BF2A6-111B-49FB-858A-B876679476CAQ33919973-D6BCC32D-66F5-4B7A-8CFC-D96443D272A3Q34076988-7C5098AF-46F6-46BB-9B50-FC98EF38DE44Q34334118-36B2A482-9469-4AC3-83E9-D44240FEA304Q34363118-6F6FEDB1-A4EA-40B6-8BD3-A0DA8AEC023EQ34410451-E19AE5FD-F05F-4268-AA7E-99A972B994F3Q34430690-0C8521C2-C94E-49AE-9870-B63088AEB1E6Q34431677-C6582F3E-203B-4591-831D-0BFBAB548F92Q35020400-56BF17F2-3B7C-4FC8-BDB3-D07723398F7CQ35095367-248F93F4-FD16-486A-B397-60A34AB33C7DQ35584122-598B75D8-77F0-453C-B644-48818F8B8855Q35849799-F3F9EA1A-5CD3-4E56-9D92-1FF79C9298EFQ35947438-2E7A87AC-A8C3-4987-A6EF-2B367C5B1155Q36009365-6495C4E3-B275-46A0-A972-4AB72E5D1DB6
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
The global situation of MDR-TB.
@ast
The global situation of MDR-TB.
@en
type
label
The global situation of MDR-TB.
@ast
The global situation of MDR-TB.
@en
prefLabel
The global situation of MDR-TB.
@ast
The global situation of MDR-TB.
@en
P1433
P1476
The global situation of MDR-TB.
@en
P2093
Marcos A Espinal
P356
10.1016/S1472-9792(02)00058-6
P577
2003-01-01T00:00:00Z